| Indicators | Browse All

Liquidia Corporation (LQDA)

Healthcare | Drug Manufacturers - Specialty & Generic | Morrisville, United States | NasdaqCM
34.58 USD -0.20 (-0.589%) ⇩ (Oct. 16, 2026, 3:32 p.m. EDT)

Short-term:★★☆☆☆Long-term:★★★⯪☆Dividends:☆☆☆☆☆
Hot Take ↕ | Oct. 10, 2026, 8:15 a.m. EDT

The investment case here is defined by a stark disconnect between the company's explosive recent performance and its current valuation reality. Fundamentally, the business is exceptional: revenue is growing at nearly 18%, operating margins are nearly 50%, and the return on equity is a staggering 132%. The market has punished the stock hard, sending it down roughly 88% from its peak, which has created a compelling entry point for long-term investors who can ignore the noise. The forward P/E of roughly 12x suggests the market is pricing in a significant slowdown or a complete failure of the bull thesis, despite the analyst consensus still being a 'Buy' with a target price nearly double the current level. However, the short-term outlook is fraught with danger due to the recent price action. The stock has suffered a brutal collapse in the last two weeks, dropping from the high 70s to the mid-20s. This creates a precarious technical setup where the immediate trend is violently bearish, even though the longer-term trend remains intact. The options market reflects this tension, with traders buying deep calls hoping for a V-shaped recovery while simultaneously selling puts to cap their downside risk. Until the price stabilizes above the 50-day moving average, the momentum is broken, making this a risky trade for the near term. For the patient investor, the fundamentals are unambiguously excellent, but the timing requires caution.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.297199
AutoETS0.297206
MSTL0.298550
AutoTheta0.310741

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 16%
H-stat 353.32
Ljung-Box p 0.000
Jarque-Bera p 0.013
Excess Kurtosis -0.97
Attribute Value
Sector Healthcare
Debt to Equity Ratio 93.738
Revenue per Share 5.148
Market Cap 3,094,769,920
Trailing P/E 24.87
Forward P/E 15.81
Beta 0.61
Profit Margins 30.74%
Previous Name Liquidia Technologies, Inc.
Website https://www.liquidia.com

As of Oct. 10, 2026, 8:15 a.m. EDT: Speculators are positioning for a volatile recovery with heavy call volume at strikes significantly above the current price (30, 50, 85, 125), suggesting a belief in a sharp upward move. However, put writing remains substantial at lower strikes (20, 25, 27.5), creating a 'strangle' style setup where traders are betting on a large gap up while protecting against a drop back to the lows. The massive implied volatility spikes at deep out-of-the-money strikes indicate fear of extreme moves in either direction.


Info Dump

Attribute Value
52 Week Change 0.547153
Address1 419 Davis Drive
Address2 Suite 100
All Time High 93.61
All Time Low 2.25
Ask 33.79
Ask Size 1
Audit Risk 8
Average Analyst Rating 1.8 - Buy
Average Daily Volume10 Day 7,774,550
Average Daily Volume3 Month 3,051,428
Average Volume 3,051,428
Average Volume10Days 7,774,550
Beta 0.61
Bid 24.7
Bid Size 2
Board Risk 9
Book Value 2.19
City Morrisville
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 6
Country United States
Crypto Tradeable 0
Currency USD
Current Price 34.575
Current Ratio 2.312
Custom Price Alert Confidence HIGH
Date Short Interest 1,790,726,400
Day High 34.9
Day Low 33.33
Debt To Equity 93.738
Display Name Liquidia
Dividend Yield 0.0
Earnings Call Timestamp End 1,786,537,800
Earnings Call Timestamp Start 1,786,537,800
Earnings Timestamp 1,786,537,800
Earnings Timestamp End 1,793,709,000
Earnings Timestamp Start 1,793,709,000
Ebitda 169,768,000
Ebitda Margins 0.3765
Enterprise To Ebitda 17.741
Enterprise To Revenue 6.68
Enterprise Value 3,011,834,112
Eps Current Year 2.02714
Eps Forward 2.18714
Eps Trailing Twelve Months 1.39
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 15
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 919 328 4402
Fifty Day Average 61.6208
Fifty Day Average Change -27.0458
Fifty Day Average Change Percent -0.43890697
Fifty Two Week Change Percent 54.7153
Fifty Two Week High 93.61
Fifty Two Week High Change -59.035
Fifty Two Week High Change Percent -0.63064843
Fifty Two Week Low 21.94
Fifty Two Week Low Change 12.635
Fifty Two Week Low Change Percent 0.5758888
Fifty Two Week Range 21.94 - 93.61
Financial Currency USD
First Trade Date Milliseconds 1,532,611,800,000
Float Shares 65,217,073
Forward Eps 2.18714
Forward P E 15.808316
Free Cashflow 74,296,128
Full Exchange Name NasdaqCM
Full Time Employees 216
Fullday Change -0.20499802
Fullday Change Percent -0.5894135
Fullday Price 34.575
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,790,812,800
Gross Margins 0.92542
Gross Profits 417,276,992
Has Pre Post Market Data 1
Held Percent Insiders 0.09212
Held Percent Institutions 0.81859
Implied Shares Outstanding 89,508,891
Industry Drug Manufacturers - Specialty & Generic
Industry Disp Drug Manufacturers - Specialty & Generic
Industry Key drug-manufacturers-specialty-generic
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Long Name Liquidia Corporation
Market us_market
Market Cap 3,094,769,920
Market State REGULAR
Max Age 86,400
Message Board Id finmb_22761611
Most Recent Quarter 1,782,777,600
Name Change Date 2,026-10-16
Net Income To Common 138,606,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 6,040,955,053
Number Of Analyst Opinions 8
Open 34.78
Operating Cashflow 167,708,000
Operating Margins 0.49812
Overall Risk 7
Payout Ratio 0.0
Phone 919 328 4400
Prev Name Liquidia Technologies, Inc.
Previous Close 34.78
Price Eps Current Year 17.056051
Price Hint 2
Price To Book 15.787671
Price To Sales Trailing12 Months 6.863433
Profit Margins 0.30739
Quick Ratio 2.075
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key buy
Recommendation Mean 1.75
Region US
Regular Market Change -0.20499802
Regular Market Change Percent -0.5894135
Regular Market Day High 34.9
Regular Market Day Low 33.33
Regular Market Day Range 33.33 - 34.9
Regular Market Open 34.78
Regular Market Previous Close 34.78
Regular Market Price 34.575
Regular Market Time 1,792,179,176
Regular Market Volume 2,655,088
Return On Assets 0.27039
Return On Equity 1.3181599
Revenue Growth 18.427
Revenue Per Share 5.148
Sand P52 Week Change 0.16207206
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 6
Shares Outstanding 89,508,891
Shares Percent Shares Out 0.1412
Shares Short 12,640,721
Shares Short Previous Month Date 1,788,134,400
Shares Short Prior Month 11,858,334
Short Name Liquidia Corporation
Short Percent Of Float 0.1752
Short Ratio 5.68
Source Interval 15
State NC
Symbol LQDA
Target High Price 70.0
Target Low Price 33.0
Target Mean Price 54.375
Target Median Price 56.5
Total Cash 284,180,992
Total Cash Per Share 3.175
Total Debt 182,896,000
Total Revenue 450,907,008
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps 1.39
Trailing P E 24.874102
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 53.92535
Two Hundred Day Average Change -19.35035
Two Hundred Day Average Change Percent -0.35883585
Type Disp Equity
Volume 2,655,088
Website https://www.liquidia.com
Zip 27,560